pre-IPO PHARMA

COMPANY OVERVIEW

BlueWillow Biologics is developing a new generation of safe and effective nasal vaccines to help protect humankind from respiratory infections, sexually transmitted diseases and food allergies. Our novel intranasal antigen delivery technology platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including COVID-19,


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.bluewillow.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Mar 2, 2022

BlueWillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal COVID-19 Booster Candidate in Pre-clinical Studies


Oct 26, 2021

BlueWillow Biologics to Present During BARDA Industry Day 2021


Sep 21, 2021

BlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board


Aug 24, 2021

BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine


Nov 10, 2020

Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2


For More Press Releases


Google Analytics Alternative